

10729856

Connecting via Winsock to STN

Text:

"x-ray" "x-ray diffract?" or "XRD" or "XRPD"
"Cetirizine" "dihydrochloride"

or "x-ray powder diffract?"

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced
with preparation role

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may

10729856

result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 16:53:53 ON 18 NOV 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:54:05 ON 18 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 NOV 2006 HIGHEST RN 913607-70-2

DICTIONARY FILE UPDATES: 17 NOV 2006 HIGHEST RN 913607-70-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10729856.str



chain nodes :

7 8 9 10 11 12 25

ring nodes :

1 2 3 4 5 6 13 14 15 16 17 18 19 20 21 22 23 24

10729856

chain bonds :

3-12 6-7 7-8 8-9 9-10 10-11 12-13 12-14 17-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-20 13-24 14-15 14-19 15-16 16-17 17-18

18-19 20-21 21-22 22-23 23-24

exact/norm bonds :

1-2 1-6 2-3 3-4 3-12 4-5 5-6 6-7 8-9 9-10

exact bonds :

7-8 10-11 12-13 12-14 17-25

normalized bonds :

13-20 13-24 14-15 14-19 15-16 16-17 17-18 18-19 20-21 21-22 22-23 23-24

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom


20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:54:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 17 TO ITERATE

100.0% PROCESSED 17 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

10729856

BATCH **COMPLETE**
PROJECTED ITERATIONS: 93 TO 587
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:54:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 351 TO ITERATE

100.0% PROCESSED 351 ITERATIONS 39 ANSWERS
SEARCH TIME: 00.00.01

L3 39 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 166.94 167.15

FILE 'HCAPLUS' ENTERED AT 16:54:33 ON 18 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2006 VOL 145 ISS 22
FILE LAST UPDATED: 17 Nov 2006 (20061117/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1011 L3

=> s l4 and cyrstal?
326 CYRSTAL?
L5 0 L4 AND CYRSTAL?

=> s l4 and crystal?
1792725 CRYSTAL?
L6 17 L4 AND CRYSTAL?

=> d ed abs ibib hitstr 1-17

L6 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 19 May 2006
 AB There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked

active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insol. polymer and at least one gastrosol. inorg. or organic pore-former, exhibit a pleasant taste when placed in

the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach. Thus, microgranules were prepared containing cetirizine hydrochloride hydrochloride 20 %, microcryst. cellulose 70 % and Methocel K100LV at 10 % were granulated. The microgranules (700 mg) obtained above were microencapsulated using ethylcellulose 300 g and calcium carbonate 150 g.

ACCESSION NUMBER: 2006:469354 HCAPLUS
 DOCUMENT NUMBER: 144:474945
 TITLE: Taste-masked pharmaceutical compositions comprising water-insol. polymer and a pore-former prepared by coacervation
 INVENTOR(S): Lai, Jin-Wang; Qian, Ken Kangyi; Venkatesh, Gopi M.
 PATENT ASSIGNEE(S): Euraand Pharmaceuticals Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 15 pp.
 CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006105038	A1	20060518	US 2005-213266	20050826
WO 2006055142	A2	20060526	WO 2005-US37084	20051013
WO 2006055142	A3	20060720		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:
 US 2004-627525P P 20041112
 US 2005-213266 A 20050826

IT 83881-52-1, Cetirizine hydrochloride

L6 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 05 May 2006
 AB There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked

active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insol. polymer and one

or more gastrosol. inorg. or organic pore-formers (practically insol. in water

and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

Diphenhydramine hydrochloride (375 g) was slowly added to an aqueous solution of

41.8 g polyvinylpyrrolidone and 1667 g of purified water and mixed well. Sugar spheres (60-80 mesh, 1470 g) were coated with the above formulation and the drug containing pellets were dried, and a seal coat of Opadry

Clear for a weight gain of 4% was applied to the drug-layered beads. Thus, 1000 g

of drug-layered beads produced above were coated with a membrane comprising 227.3 g of EC-10, 22.7 g of Myvacet 9-45 (diacetylatedmonoglyceride) and 68.2 g of calcium carbonate dissolved/suspended in 3916.6 g of 95/5 acetone/water. The coated beads were dried and their dissoln. profiles was studied.

ACCESSION NUMBER: 2006:410144 HCAPLUS
 DOCUMENT NUMBER: 144:440104
 TITLE: Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
 INVENTOR(S): Lai, Jin-Wang; Venkatesh, Gopi M.; Qian, Ken Kangyi
 PATENT ASSIGNEE(S): Euraand Pharmaceuticals Limited, Ire.
 SOURCE: PCT Int. Appl., 34 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006047493	A2	20060504	WO 2005-US38328	20051021


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006105039 A1 20060518 20051021
 PRIORITY APPLN. INFO.: US 2004-621144P P 20041021


Page 518/11/2006

L6 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (taste-masked pharmaceutical compns. comprising water-insol. polymer and a pore-former)
 RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 83881-51-0, Cetirizine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (taste-masked pharmaceutical compns. comprising water-insol. polymer and a pore-former)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L6 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IT 83881-51-0, Cetirizine 83881-52-1, Cetirizine dihydrochloride
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (taste-masked pharmaceutical compns. with gastrosol. pore-formers)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



10729856


L6 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 13 Apr 2006
 AB There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 s forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insol. and gastro-soluble polymers release not less than about 60% of the dose in the stomach in about 30 min, thus maximizing the probability of achieving bioequivalence to the reference immediate-release product having rapid onset of action (short T_{max}). A process for preparing such compns. for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed. For example, drug-layered cetirizine dihydrochloride beads (drug load: 8.4%) were prepared by coating sugar spheres with an aqueous solution of cetirizine dihydrochloride and polyvinylpyrrolidone to obtain pellets and seal coating the pellets with Opadry Clear. The beads were then coated with Et cellulose/Eudragit E100 with Myvacet 9-45/talc to give taste-masked beads. The taste-masked beads coated at 20% released 13% drug in 5 min using the USP Apparatus 2. Taste-masked beads at 20% coating, rapidly-dispersing microgranules, crospovidone, flavor, and Aspartame would be blended and compressed into orally disintegrating tablets containing 10 mg of cetirizine dihydrochloride.

ACCESSION NUMBER: 2006:341597 HCAPLUS
 DOCUMENT NUMBER: 144:376503
 TITLE: Taste-masked pharmaceutical compositions
 INVENTOR(S): Venkatesh, Gopi M.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 15 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006078614	A1	20060413	US 2005-248596	20051012
PRIORITY APPLN. INFO.:			US 2004-617737P	P 20041012

IT 83881-51-0, Cetirizine 83881-52-1, Cetirizine dihydrochloride
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (orally disintegrating tablets comprising taste-masked microparticles and rapidly-dispersing microgranules)
 RN 83881-51-0 HCAPLUS

L6 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


L6 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 17 Jun 2005
 AB A multiparticulate for controlled release of a crystalline drug comprises a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a Poloxamer, wherein at least 70 weight% of the drug in the multiparticulate is crystalline. Thus, azithromycin-containing multiparticulates were prepared via a melt-congeal process from a mixture containing azithromycin/Compritol 888 ATO/Pluronic (50:40:10) forming a preblend and extrusion of the preblend at a feed rate of 130 g/min. More than 90 weight% of the azithromycin in the multiparticulates was crystalline dihydrate. The release rate of azithromycin from the multiparticulates was 32, 67, 90, 99, 99, and 100% in 5, 15, 30, 60, 120, and 180 min, resp.

ACCESSION NUMBER: 2005:523256 HCAPLUS
 DOCUMENT NUMBER: 143:65406
 TITLE: Multiparticulate crystalline drug compositions containing a Poloxamer and a glyceride
 INVENTOR(S): Appel, Leah Elizabeth; Crew, Marshall David; Friesen, Dwayne Thomas; Herbig, Scott M.; Lo, Julian Belknap; Lyon, David Keith; McCray, Scott Bladwin; Ray, Roderick Jack; West, James Blair
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053652	A1	20050616	WO 2004-1B3808	20041122
WO 2005053652	C1	20050804		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005181062	A1	20050818	US 2004-4168	20041203
PRIORITY APPLN. INFO.:			US 2003-527329P	P 20031204

IT 83881-51-0, Cetirizine
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (multiparticulate compns. containing glyceride and Poloxamer for controlled release of crystalline drug)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

- Compos.
 11/004,168

10729856

L6 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 28 Jan 2005
 AB A novel crystalline form of cetirizine monohydrochloride and processes for making the crystalline form as well as compns., pharmaceutical compns., and methods utilizing the crystalline form are described. A process for preparation of a crystalline form of cetirizine monohydrochloride, comprises (1) providing a solid residue of crude cetirizine monohydrochloride; (2) contacting the crude residue with a ketone solvent to cause separation of a solid mass; and (3) isolating the solid mass thereby obtaining the crystalline form of cetirizine monohydrochloride. Tablets for the treatment of allergic syndromes were formulated containing crystalline cetirizine monohydrochloride 10, CaCO₃ 500, PVP 17, Avicel 15, mannitol 400, maltodextrin 15, aspartame 3, and aroma 20 mg each.

ACCESSION NUMBER: 2005:78236 HCAPLUS
 DOCUMENT NUMBER: 142:162672
 TITLE: Crystalline cetirizine monohydrochloride
 INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Rao, Uppala Venkata Bhaskara; Reddy, Konda
 PATENT ASSIGNEE(S): Srinivasa Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
 SOURCE: U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020608	A1	20050127	US 2004-809192	20040325
PRIORITY APPLN. INFO.:			IN 2003-MA252	A 20030325


IT 798544-25-9P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
 RN 798544-25-9 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 31 Dec 2004
 AB An amorphous form of the antiallergic compound cetirizine dihydrochloride, prepared by the base-promoted hydrolysis of the corresponding amide of cetirizine, extraction, followed by HCl salification, is prepared as are pharmaceutical compns. utilizing this crystalline form.

ACCESSION NUMBER: 2005:2182 HCAPLUS
 DOCUMENT NUMBER: 142:93859
 TITLE: Process for the preparation of an amorphous crystal form of the antiallergic cetirizine dihydrochloride
 INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Rao, Uppala Venkata Bhaskara; Reddy, Konda
 PATENT ASSIGNEE(S): Srinivasa Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
 SOURCE: U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004266787	A1	20041230	US 2004-809193	20040325
PRIORITY APPLN. INFO.:			IN 2003-MA253	A 20030325

IT 83881-51-0P, Cetirizine
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (in a process for the preparation of an amorphous crystal form of the antiallergic cetirizine dihydrochloride)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, (9CI) (CA INDEX NAME)




IT 83881-52-1P, Cetirizine dihydrochloride
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (process for the preparation of an amorphous crystal form of the antiallergic cetirizine dihydrochloride)
 RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

IT 83881-51-0P, Cetirizine
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, (9CI) (CA INDEX NAME)




IT 83881-52-1P, Cetirizine dihydrochloride
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
 RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L6 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

L6 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ED Entered STN: 18 Jun 2004
 AB Crystalline polymorphic forms of the levorotatory and dextrorotatory cetirizine dihydrochloride salts are prepared by dissolving the salts in an a ketone-containing solvent (e.g., aqueous acetone), cooling the solution, and collecting the crystalline precipitate
 ACCESSION NUMBER: 2004:493694 HCAPLUS
 DOCUMENT NUMBER: 141:54360
 TITLE: Polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation
 INVENTOR(S): Reddy, Manne Satyanarayana; Srinivasan, Thirumalai Rajan; Uppala, Venkata Bhaskara Rao; Vaddadi, Pattabhi
 PATENT ASSIGNEE(S): Ramayya, Joga, Rajender Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
 SOURCE: PCT Int. Appl., 37 pp. CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050647	A2	20040617	WO 2003-US38494	20031204
WO 2004050647	A3	20040902		
WO 2004050647	C1	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD			
CA 2488114	AA	20040617	CA 2003-2488114	20031204
AU 2003297640	A1	20040623	AU 2003-297640	20031204
US 2004186112	A1	20040923	US 2003-729856	20031204
CN 1692105	A	20051102	CN 2003-801009-3	20031204
PRIORITY APPLN. INFO:			IN 2002-MA908	A 20021204
			WO 2003-US38494	W 20031204


IT 130018-87-0P 163837-48-7P
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 and (polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation)

L6 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 130018-77-8 HCAPLUS
 CN Acetic acid, [2-[(4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry. Rotation (+).



L6 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 RN 130018-87-0 HCAPLUS
 CN Acetic acid, [2-[(4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)]


Absolute stereochemistry. Rotation (+).



● 2 HCl

RN 163837-48-7 HCAPLUS
 CN Acetic acid, [2-[(4-[(S)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)]

Absolute stereochemistry. Rotation (-).



● 2 HCl

IT 130018-76-7P, Dextrocetirizine 130018-77-8P, Levocetirizine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 and (polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation from)

RN 130018-76-7 HCAPLUS
 CN Acetic acid, [2-[(4-[(S)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry. Rotation (-).

L6 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ED Entered STN: 08 Apr 2004
 AB A chewing gum comprising at least two different biodegradable polymers exhibits an improved texture prior to any adding of for example softeners


It has been realized that the desired chewing gum texture properties, contrary to every expectation and any prior art disclosures, may be actually be obtained when combining biodegradable chewing gum polymers, for example in the gum base or in the final gum. Thus, a peppermint chewing gum formulation contains gum base 40, sorbitol 48.6, lycasin 3, peppermint oil 1.5, menthol crystals 0.5, aspartame 0.2, acesulfame 0.2, and xylitol 6 weights.

ACCESSION NUMBER: 2004:290440 HCAPLUS
 DOCUMENT NUMBER: 140:320320
 TITLE: Chewing gum comprising at least two different biodegradable polymers
 INVENTOR(S): Andersen, Lone; Wittorff, Helle
 PATENT ASSIGNEE(S): Gumlink A/S, USA
 SOURCE: PCT Int. Appl., 59 pp. CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028268	A1	20040408	WO 2002-DK627	20020924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TP, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2500976	AA	20040408	CA 2002-2500976	20020924
AU 2002340774	A1	20040419	AU 2002-340774	20020924
BR 2002015888	A	20050726	BR 2002-15888	20020924
EP 1562439	A1	20050817	EP 2002-774470	20020924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
CN 1668208	A	20050914	CN 2002-829650	20020924
JP 200600041	T2	20060105	JP 2004-538758	20020924
CA 2499998	AA	20040408	CA 2003-2499998	20030924
WO 2004028270	A1	20040408	WO 2003-DK626	20030924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003266215	A1	20040419	AU 2003-266215	20030924
EP 1545234	A1	20050629	EP 2003-798088	20030924


L6 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003014678 A 20050802 BR 2003-14678 20030924
 JP 2006500044 T2 20060105 JP 2004-538771 20030924
 CN 1728949 A 20060201 CN 2003-822649 20030924
 US 2005244538 A1 20051103 US 2005-88109 20050323
 US 2006240143 A1 20061026 US 2005-528926 20051216
 PRIORITY APPLN. INFO.: WO 2002-DK627 W 20020924
 WO 2003-DK626 W 20030924

IT 83881-51-0 130018-77-8
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (chewing gum comprising at least two different biodegradable polymers)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
 (9CI) (CA INDEX NAME)



RN 130018-77-8 HCAPLUS
 CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L6 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 08 Apr 2004
 AB A chewing gum comprises at least one biodegradable polyester copolymer
 obtained by the polymerization of two or more cyclic esters by
 ring-opening. At least one biodegradable polyester copolymer has a mol. weight of less
 than 150000 g/mol and the chewing gum further comprises chewing gum
 ingredients. An improved release of chewing gum ingredients has been
 obtained when a texture acceptable biodegradable polyester copolymer are
 applied as a chewing gum polymer. Thus, a chewing gum formulation
 contains gum base 40, sorbitol 48.6, lycasin 3, peppermint oil 1.5,
 menthol crystals 0.5, aspartame 0.2, acesulfame 0.2, and xylitol
 5 weights.
 ACCESSION NUMBER: 2004:290439 HCAPLUS
 DOCUMENT NUMBER: 140:320319
 TITLE: Chewing gum having improved release of chewing gum
 ingredients
 INVENTOR(S): Andersen, Lone; Wittorf, Helle
 PATENT ASSIGNEE(S): Gumlink A/S, Den.
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028267	A1	20040408	WO 2002-DK626	20020924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2500026	AA	20040408	CA 2002-2500026	20020924
AU 2002342579	A1	20040419	AU 2002-342579	20020924
EP 1549153	A1	20050706	EP 2002-779229	20020924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002015887	A	20050726	BR 2002-15887	20020924
CN 1668206	A	20050914	CN 2002-829648	20020924
JP 2006500040	T2	20060105	JP 2004-538757	20020924
US 2006099300	A1	20060511	US 2005-529133	20050906
PRIORITY APPLN. INFO.:			WO 2002-DK626	W 20020924


IT 83881-51-0 130018-77-8
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (chewing gum having improved release of chewing gum ingredients)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-

L6 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)



RN 130018-77-8 HCAPLUS
 CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L6 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 08 Apr 2004
 AB A chewing gum comprises at least one biodegradable polymer, wherein the
 mol. weight of said polymer is at least 105000 g/mol (Mn). According to
 the invention, it has moreover been realized that this problem may be
 effectively dealt with by increasing the mol. weight of at least one of
 the biodegradable polymers in the chewing gum when compared to conventional
 chewing gum polymers and thereby increasing the robustness of the chewing
 gum with respect to softeners, emulsifiers and e.g. flavor. Thus,
 chewing gum ingredients contain gumbase 40, sorbitol powder 45.6, lycasin 3,
 peppermint oil 1.5, menthol crystal 0.5, aspartame 0.2,
 acesulfame 0.2, and xylitol 61.


ACCESSION NUMBER: 2004:290438 HCAPLUS
 DOCUMENT NUMBER: 140:320318
 TITLE: Biodegradable chewing gum comprising at least one
 high molecular weight biodegradable polymer
 INVENTOR(S): Andersen, Lone; Wittorf, Helle
 PATENT ASSIGNEE(S): Gumlink A/S, Den.
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028266	A1	20040408	WO 2002-DK625	20020924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2500022	AA	20040408	CA 2002-2500022	20020924
AU 2002342578	A1	20040419	AU 2002-342578	20020924
EP 1542542	A1	20050622	EP 2002-779228	20020924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002015890	A	20050726	BR 2002-15890	20020924
CN 1668209	A	20050914	CN 2002-829651	20020924
JP 2006500039	T2	20060105	JP 2004-538756	20020924
US 2006165842	A1	20060727	US 2005-528927	20051216
PRIORITY APPLN. INFO.:			WO 2002-DK625	W 20020924

IT 83881-51-0, Cetirizine 130018-77-8, Levocetirizine
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (low moisture chewing gum comprising biodegradable polymer)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
 (9CI) (CA INDEX NAME)


10729856

L6 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 130018-77-8 HCAPLUS
 CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L6 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 130018-77-8 HCAPLUS
 CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L6 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 08 Apr 2004

AB Chewing gum comprises at least one biodegradable polymer and chewing gum ingredients. Chewing gum contains less than about 2.0 weight percent water

of the chewing gum. The biodegradable chewing gum having low moisture was

provided in combination with an initial acceptable texture. Thus, a chewing gum formulation contains gum base 40, sorbitol 48.6, maltitol syrup 3, peppermint oil 1.5, menthol crystals 0.5, aspartame 0.2, acesulfame 0.2, xylitol 6, and water 1.5%.

ACCESSION NUMBER: 2004:290437 HCAPLUS

DOCUMENT NUMBER: 140:320317

TITLE: Low moisture chewing gum comprising biodegradable polymer

INVENTOR(S): Andersen, Lone; Wittorf, Helle

PATENT ASSIGNEE(S): Gumlink A/S, Den.

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028265	A1	20040408	WO 2002-DK624	20020924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2500000	AA	20040408	CA 2002-2500000	20020924
AU 2002342577	A1	20040419	AU 2002-342577	20020924
EP 1542541	A1	20050622	EP 2002-779227	20020924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002015889	A	20050726	BR 2002-15889	20020924
CN 1703150	A	20051130	CN 2002-829647	20020924
JP 2006500038	T2	20060105	JP 2004-538755	20020924
US 2006246174	A1	20061102	US 2005-529137	20050906
PRIORITY APPLN. INFO.:			WO 2002-DK624	W 20020924

IT 83881-51-0 130018-77-8

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (low moisture chewing gum comprising biodegradable polymer)

RN 83881-51-0 HCAPLUS

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)

L6 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 08 Apr 2004

AB Degradable chewing gum polymer is a polymer polymerized from at least one trifunctional or higher functional initiator, at least two different monomers forming the backbone of the polymer and at least one monomer selected from the group of carbonate monomers. It has been realized that a certain degree of branching of the backbone is needed to obtain a final improved performance, when the polymer, preferably the elastomer, is incorporated in a chewing gum. It has moreover been realized that the obtained degree of branching needs and may actually be carefully controlled in order to avoid too much branching-induced crosslinking. Thus, a chewing gum formulation contains gum base 40, sorbitol 48.6, lycopodium 3, peppermint oil 1.5, menthol crystals 0.5, aspartame 0.2, acesulfame 0.2, and xylitol 6 weight%.

ACCESSION NUMBER: 2004:287754 HCAPLUS

DOCUMENT NUMBER: 140:320316

TITLE: Degradable chewing gum polymer

INVENTOR(S): Andersen, Lone; Wittorf, Helle; Storey, Robson;

Desai, Ganesh S.

PATENT ASSIGNEE(S): Gumlink A/S, Den.

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028269	A1	20040408	WO 2002-DK628	20020924
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2501059	AA	20040408	CA 2002-2501059	20020924
AU 2002342580	A1	20040419	AU 2002-342580	20020924
EP 1549154	A1	20050706	EP 2002-779230	20020924
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002015885	A	20050726	BR 2002-15885	20020924
CN 1668207	A	20050914	CN 2002-829649	20020924
JP 2006500445	T2	20060105	JP 2004-538759	20020924
US 2006121156	A1	20060608	US 2005-528930	20050906
PRIORITY APPLN. INFO.:			WO 2002-DK628	W 20020924

IT 83881-51-0 130018-77-8

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (biodegradable chewing gum polymer prepared by ring-opening


polymerization)

RN 83881-51-0 HCAPLUS

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-(9CI) (CA INDEX NAME)


10729856

L6 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 130018-77-8 HCAPLUS
 CN Acetic acid, [2-[(4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L6 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 21 Dec 2003
 AB A novel, amorphous form of [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]acetic acid dihydrochloride, suitable for pharmaceutical formulations, is prepared and X-ray diffraction patterns for


it are presented.

ACCESSION NUMBER: 2003:991495 HCAPLUS
 DOCUMENT NUMBER: 140:47519
 TITLE: Process for the preparation of an amorphous form of [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride)
 INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Shankar, Ranga Ravi; Vardhan, Sunkara Vishnu
 PATENT ASSIGNEE(S): Dr.Reddy's Laboratories Ltd., India; Dr.Reddy's Laboratories, Inc.
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104212	A1	20031218	WO 2003-US17600	20030604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003238893	A1	20031222	AU 2003-238893	20030604
PRIORITY APPLN. INFO.:			IN 2002-MA425	A 20020605
			WO 2003-US17600	W 20030604

IT 83881-51-OP, Cetirizine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in a process for the preparation of an amorphous form of [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 83881-52-1P, Cetirizine dihydrochloride
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
 (process for the preparation of an amorphous form of [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
 RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L6 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 21 Dec 2003
 AB A crystalline form of cetirizine dihydrochloride (I), prepared by the salification of cetirizine with isopropanolic hydrogen chloride, having a defined X-ray diffraction pattern is presented, and pharmaceutical compns.


containing I are presented.

ACCESSION NUMBER: 2003:991494 HCAPLUS
 DOCUMENT NUMBER: 140:42205
 TITLE: Preparation of crystalline [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride)
 INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Shankar, Ranga Ravi; Vardhan, Sunkara Vishnu
 PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104211	A2	20031218	WO 2003-US17672	20030604
WO 2003104211	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003237394	A1	20031222	AU 2003-237394	20030604
PRIORITY APPLN. INFO.:			IN 2002-MA425	A 20020605
			WO 2003-US17672	W 20030604


OTHER SOURCE(S): CASREACT 140:42205
 IT 83881-52-1P, Cetirizine dihydrochloride
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of crystalline [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
 RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[(4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

IT 83881-51-0P, Cetirizine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (salification with HCl of)
 RN 83881-51-0 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




L6 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 01 Aug 2003
 AB A tablet and a process for its manufacture are described where a drug having a defined rate of delivery is applied by compression onto a compressible coating deposited on a tablet having the same or a different in vivo drug release profile. For the compressible coating, an acrylic acid, methacrylic acid, or ester of either is the preferred monomer for making the polymer in the coating. A pseudoephedrine tablet blend was obtained from pseudoephedrine-HCl (crystals) 75.4, Avicel PH101 21.2, Klucel TM 3.4, and water 81. A 2-kg batch is prepared by first dry mixing the above powders in a high-shear granulator. The water (160 g) is added at 60 g/min, then the sample mixed for an addnl. 30 s to give a total mix time of 8 min. The granulation is then spread on a polyethylene lined tray and dried 16 h at 50°. The granulation is then passed through a mill. A final pseudoephedrine tablet blend (containing 44.9% pseudoephedrine) is prepared by combining the components below without the magnesium stearate at the designated percentages and blending in a V-blender for 15 min followed by an addnl. 5-min after addition of the magnesium stearate: pseudoephedrine granulation- Part A 59.5, Avicel-PH200 40.0, and Mg stearate 0.5%. A water-permeable compressible coating containing PEG, Eudragit RL, and tri-Et citrate was applied.
 ACCESSION NUMBER: 2003:590609 HCAPLUS
 DOCUMENT NUMBER: 139:122800
 TITLE: Manufacture of tablets containing polymers
 INVENTOR(S): Waterman, Kenneth C.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 99,715.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003143272	A1	20030731	US 2002-243332	20020913
US 2003039691	A1	20030227	US 2002-99715	20020313
US 2006105040	A1	20060518	US 2006-332005	20060112
PRIORITY APPLN. INFO.:			US 2001-275899P	P 20010314
			US 2002-99715	A2 20020313

IT 83881-52-1, Cetirizine hydrochloride
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (manufacture of tablets containing polymers)
 RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

L6 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN


ED Entered STN: 04 Jul 2003
 AB Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage form is disrupted. Methods of administering pharmaceuticals by providing pharmaceutical safety dosage forms are also provided. The pharmaceutical is adapted for time-release, or the antagonist comprises an insol. coating, or both. The bioavailability occurs upon mech. disruption. The dosage form is adapted to be administered rectally, parenterally, vaginally, transdermally, intranasally, or via an aerosol.
 ACCESSION NUMBER: 2003:511826 HCAPLUS
 DOCUMENT NUMBER: 139:74068
 TITLE: Pharmaceutical safety dosage forms
 INVENTOR(S): Roberts, Richard H.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003124061	A1	20030703	US 2003-339977	20030110
CA 2505661	AA	20040729	CA 2003-2505661	20031218
WO 2004062642	A1	20040729	WO 2003-US40990	20031218
WO 2004062642	B1	20041021		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TH, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG AU 2003299826	A1	20040810	AU 2003-299826	20031218
EP 1581188	A1	20051005	EP 2003-800100	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514067	T2	20060427	JP 2004-566589	20031218
PRIORITY APPLN. INFO.:			US 2003-339977	A 20030110
			WO 2003-US40990	W 20031218

IT 83881-52-1, Cetirizine hydrochloride
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical safety dosage forms)
 RN 83881-52-1 HCAPLUS
 CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

10729856

L6 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl

L6 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 11 May 2001

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected

to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predicted to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

ACCESSION NUMBER: 2001:338762 HCAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001032928	A2	20010510	WO 2000-US30474	20001103	
WO 2001032928	A3	20020725			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: CH, GM, KE, LS, MW, MG, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
PRIORITY APPLN. INFO.:				US 1999-165398P	P 19991105
				US 2000-196571P	P 20000411


IT 83881-51-0, Cetirizine
RL: BAC (Biological activity or effector, except adverse): BSU
(Biological)

L6 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
study, unclassified); BIOL (Biological study)
(methods of detg. individual hypersensitivity to a pharmaceutical

agent from gene expression profile)

RN 83881-51-0 HCAPLUS

CN Acetic acid, [2-[[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-
(9CI) (CA INDEX NAME)



10729856

=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE

ENTRY

94.46

SINCE FILE

ENTRY

-12.75

TOTAL

SESSION

261.61

TOTAL

SESSION

-12.75

STN INTERNATIONAL LOGOFF AT 16:56:07 ON 18 NOV 2006